Miocamycin pharmacokinetics in hepatopathic patients

V. Carnelli, A. Turconi, N. Mirra, M. Falchi, R. Nebuloni, F. Ferrara

Research output: Contribution to journalArticle


The pharmacokinetics of miocamycin in young patients suffering from Cooley's disease and liver insufficiency owing to a polytransfusional hepatitis were studied. Ten patients requiring an antibacterial therapy in consequence of occasionally occurring respiratory infections were enrolled in the study. Each patient was given everyday a standard dose of 35 mg/kg of miocamycin on an empty stomach. Six subjects received two miocamycin doses of 175 mg/kg at 8 a.m. and 8 p.m., respectively (b.i.d, group) and four subjects received miocamycin 35 mg/kg at 8 a.m. (o.d. group). The test period lasted seven days. Blood samples were drawn on 1st and 7th day of therapy 0.25, 0.66, 1, 4, 6, 8, 12 hours after the 8 a.m. intake. Miocamycin serum levels were obtained using the microbiological method. In the b.i.d. group, C max of the drug was 4.55 ± 0.43 mg/l on 1st day and 5.60 ± 1.06 mg/l on 7th day; t max was 0.72 h and 0.77 h on 1st and 7th day, respectively; t 1/2 β was 1.36 h and 0.93 h on 1st and 7th day, respectively. In the o.d. group, C max was 6.08 ± 0.63 mg/l on 1st day and 6.40 ± 0.69 ml/l on 7th day; t max was 0.75 h both on 1st and 7th day; t 1/2 β was 1.66 and 1.99 h on 1st and 7th day respectively. In both b.id. and o.d. groups AUC seems to be slightly increased on 7th day. In both groups the urinary recovery of miocamycin seems to be unchanged on 7th day and the detected values appear to be higher than those observed in healthy subjects, representing at least 10% of the administered dosage. The standard regimen of 35 mg/kg/day recommended for children seems to be appropriate also in the case of liver impairment.

Original languageEnglish
Pages (from-to)505-511
Number of pages7
JournalRivista Italiana di Pediatria
Issue number5
Publication statusPublished - 1994


  • hepatopathies
  • macrolides
  • miocamycin
  • pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Miocamycin pharmacokinetics in hepatopathic patients'. Together they form a unique fingerprint.

  • Cite this

    Carnelli, V., Turconi, A., Mirra, N., Falchi, M., Nebuloni, R., & Ferrara, F. (1994). Miocamycin pharmacokinetics in hepatopathic patients. Rivista Italiana di Pediatria, 20(5), 505-511.